Benazepril vs benazepril hcl 20 mg

Monitor blood glucose and observe the patient for symptoms of hypoglycemia. Adjust the insulin dose as needed. Iron salts parenteral The risk of adverse reactions to parenteral iron eg, arthralgia, fever may be increased.

If these agents must be used concurrently, monitor the patient closely. If an interaction is suspected, discontinue one of the agents. Lithium May increase lithium levels and symptoms of lithium toxicity. Monitor lithium levels frequently. Adjust the lithium dose as needed. Consider administering an alternative antihypertensive agent.

Loop diuretics eg, bumetanide, furosemide The effects of loop diuretics may be decreased. Monitor the fluid status of the patient when benazepril is started or stopped. Adjust the loop diuretic dose as needed. Pergolide An additive or synergistic effect, resulting in profound hypotension, may occur. Consider starting with a low dose of pergolide. If BP falls, dosage reduction may be needed. Phenothiazines eg, chlorpromazine An additive or synergistic hypotensive effect with postural syncope may occur when benazepril is used with phenothiazines.

Potassium supplements, potassium-sparing diuretics eg, amiloride, spironolactone, triamterene May increase serum potassium levels. If these agents are coadministered, use with caution. Frequently monitor serum potassium and adjust the dose of either drug as needed. Salicylates eg, aspirin May reduce effects of benazepril, especially in low-renin or volume-dependent hypertensive patients.

Consider increasing the dosage of benazepril or stopping the salicylate if BP control or renal function deteriorates. Posts are for general information, are not intended to substitute for informed professional advice medical, legal, veterinary, financial, etc. The site and services are provided "as is" with no warranty or representations by JustAnswer regarding the qualifications of Experts. To see what credentials have been verified by a third-party service, please click on the "Verified" symbol in some Experts' profiles.

JustAnswer in the News: If you've got a quick question, you can try to get an answer from sites that say they have various specialists on hand to give quick answers Web sites like justanswer. Traffic on JustAnswer rose 14 percent In general, avoid combined use of RAS inhibitors. Closely monitor blood pressure, renal function and electrolytes in patients on Benazepril hydrochloride and other agents that affect the RAS.

Do not coadminister aliskiren with Benazepril hydrochloride in patients with diabetes. Monitor for signs of angioedema [see Warnings and Precautions 5. Lithium Lithium toxicity has been reported in patients receiving lithium concomitantly with Benazepril hydrochloride. Lithium toxicity was usually reversible upon discontinuation of lithium or Benazepril hydrochloride. Monitor serum lithium levels during concurrent use.

Neprilysin Inhibitor Patients taking concomitant neprilysin inhibitors may be at increased risk for angioedema [see Warnings and Precautions ]. Gold Nitritoid reactions symptoms include facial flushing, nausea, vomiting and hypotension have been reported rarely in patients on therapy with injectable gold sodium aurothiomalate and concomitant ACE inhibitor therapy. When pregnancy is detected, discontinue Benazepril hydrochloride as soon as possible.

These adverse outcomes are usually associated with use of these drugs in the second and third trimester of pregnancy. Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. Appropriate management of maternal hypertension during pregnancy is important to optimize outcomes for both mother and fetus.

In the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system for a particular patient, apprise the mother of the potential risk to the fetus. Perform serial ultrasound examinations to assess the intra-amniotic environment. If oligohydramnios is observed, discontinue Benazepril hydrochloride, unless it is considered lifesaving for the mother. Fetal testing may be appropriate, based on the week of pregnancy.

Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury. Closely observe infants with histories of in utero exposure to Benazepril hydrochloride for hypotension, oliguria, and hyperkalemia [see Use in Specific Populations 8.

Nursing Mothers Minimal amounts of unchanged Benazepril and of Benazeprilat are excreted into the breast milk of lactating women treated with Benazepril. A newborn child ingesting entirely breast milk would receive less than 0. Pediatric Use The antihypertensive effects of Benazepril hydrochloride have been evaluated in a double-blind study in pediatric patients 7 to 16 years of age [see Clinical Pharmacology The pharmacokinetics of Benazepril hydrochloride has been evaluated in pediatric patients 6 to 16 years of age [see Clinical Pharmacology Infants below the age of 1 year should not be given Benazepril hydrochloride because of the risk of effects on kidney development.

Neonates with a history of in utero exposure to Benazepril hydrochloride: If oliguria or hypotension occurs, direct attention toward support of blood pressure and renal perfusion. Benazepril, which crosses the placenta, can theoretically be removed from the neonatal circulation by these means; there are occasional reports of benefit from these maneuvers with another ACE inhibitor, but experience is limited.

Geriatric Use Of the total number of patients who received Benazepril in U. No overall differences in effectiveness or safety were observed between these patients and younger patients, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

Benazepril and Benazeprilat are substantially excreted by the kidney. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function [see Dosage and Administration 2.

Race ACE inhibitors, including Benazepril hydrochloride, as monotherapy, have an effect on blood pressure that is less in Black patients than in non-Blacks. Human overdoses of Benazepril have not been reported, but the most common manifestation of human Benazepril overdosage is likely to be hypotension, for which the usual treatment would be intravenous infusion of normal saline solution.

Hypotension can be associated with electrolyte disturbances and renal failure. Benazepril is only slightly dialyzable, but consider dialysis to support patients with severely impaired renal function [see Warnings and Precautions 5. If ingestion is recent, consider activated charcoal. Consider gastric decontamination e.

Monitor for blood pressure and clinical symptoms. Supportive management should be employed to ensure adequate hydration and to maintain systemic blood pressure. In the case of marked hypotension, infuse physiological saline solution; as needed, consider vasopressors e.

Benazepril's chemical name is 3-[[l- ethoxy-carbonyl phenyl- lS -propyl]amino]-2,3,4,5-tetrahydrooxo-lH-l- 3S -benzazepine-l-acetic acid monohydrochloride; its structural formula is Its molecular formula is C24H28N2O5. HCl, and its molecular weight is Benazeprilat, the active metabolite of Benazepril, is a non-sulfhydryl angiotensin-converting enzyme inhibitor.

Benazepril is converted to Benazeprilat by hepatic cleavage of the ester group. Each Benazepril hydrochloride tablet intended for oral administration contains 5 mg or 10 mg or 20 mg or 40 mg of Benazepril hydrochloride. In addition, each tablet contains the following inactive ingredients:

Tags: pletal medication generic kamagra soft tabs 100mg how to shoot up oxycodone 5mg